Hoth Therapeutics Net Income
| HOTH Stock | USD 0.95 0.09 10.47% |
As of the 11th of February 2026, Hoth Therapeutics retains the Risk Adjusted Performance of (0.08), market risk adjusted performance of (0.22), and Standard Deviation of 3.74. Hoth Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Hoth Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Hoth Therapeutics' valuation are provided below:We have found one hundred twenty available fundamental trends for Hoth Therapeutics, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Hoth Therapeutics regular fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 5.2 M. The Hoth Therapeutics' current Enterprise Value is estimated to increase to about (2.4 M) This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -7.4 M | -7.7 M | |
| Net Loss | -12.9 M | -12.2 M | |
| Net Loss | -7.4 M | -7.7 M | |
| Net Loss | (1.16) | (1.21) | |
| Net Income Per E B T | 0.90 | 0.80 |
Hoth | Net Income | Build AI portfolio with Hoth Stock |
The Net Income trend for Hoth Therapeutics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Hoth Therapeutics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Hoth Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Hoth Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Hoth Therapeutics financial statement analysis. It represents the amount of money remaining after all of Hoth Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Hoth Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hoth Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.19 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Hoth Net Income Regression Statistics
| Arithmetic Mean | (5,314,013) | |
| Coefficient Of Variation | (73.89) | |
| Mean Deviation | 3,436,088 | |
| Median | (2,495,525) | |
| Standard Deviation | 3,926,382 | |
| Sample Variance | 15.4T | |
| Range | 12.3M | |
| R-Value | (0.76) | |
| Mean Square Error | 7T | |
| R-Squared | 0.57 | |
| Significance | 0.0004 | |
| Slope | (587,765) | |
| Total Sum of Squares | 246.7T |
Hoth Net Income History
Other Fundumenentals of Hoth Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Hoth Therapeutics Net Income component correlations
Hoth Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Hoth Therapeutics is extremely important. It helps to project a fair market value of Hoth Stock properly, considering its historical fundamentals such as Net Income. Since Hoth Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Hoth Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Hoth Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will Hoth introduce new products? Factors like these will boost the valuation of Hoth Therapeutics. Market participants price Hoth higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Hoth Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Hoth Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Hoth Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Hoth Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Hoth Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Hoth Therapeutics or generate 0.0% return on investment in Hoth Therapeutics over 90 days. Hoth Therapeutics is related to or competes with Curis, Briacell Therapeutics, Palisade Bio, Processa Pharmaceuticals, Aspire BioPharma, Lexaria Bioscience, and FibroBiologics Common. Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical n... More
Hoth Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Hoth Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Hoth Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 13.69 | |||
| Value At Risk | (5.79) | |||
| Potential Upside | 5.83 |
Hoth Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hoth Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Hoth Therapeutics' standard deviation. In reality, there are many statistical measures that can use Hoth Therapeutics historical prices to predict the future Hoth Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.58) | |||
| Total Risk Alpha | (0.81) | |||
| Treynor Ratio | (0.23) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Hoth Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hoth Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 2.86 | |||
| Coefficient Of Variation | (896.20) | |||
| Standard Deviation | 3.74 | |||
| Variance | 13.96 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.58) | |||
| Total Risk Alpha | (0.81) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 13.69 | |||
| Value At Risk | (5.79) | |||
| Potential Upside | 5.83 | |||
| Skewness | 0.2585 | |||
| Kurtosis | 0.7432 |
Hoth Therapeutics Backtested Returns
Hoth Therapeutics holds Efficiency (Sharpe) Ratio of -0.0784, which attests that the entity had a -0.0784 % return per unit of risk over the last 3 months. Hoth Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Hoth Therapeutics' Standard Deviation of 3.74, risk adjusted performance of (0.08), and Market Risk Adjusted Performance of (0.22) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.86, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Hoth Therapeutics will likely underperform. At this point, Hoth Therapeutics has a negative expected return of -0.29%. Please make sure to check out Hoth Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Hoth Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.61 |
Good predictability
Hoth Therapeutics has good predictability. Overlapping area represents the amount of predictability between Hoth Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Hoth Therapeutics price movement. The serial correlation of 0.61 indicates that roughly 61.0% of current Hoth Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.61 | |
| Spearman Rank Test | 0.34 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Hoth Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Hoth Therapeutics reported net income of (8.19 Million). This is 102.4% lower than that of the Pharmaceuticals sector and 111.69% lower than that of the Health Care industry. The net income for all United States stocks is 101.43% higher than that of the company.
Hoth Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hoth Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hoth Therapeutics could also be used in its relative valuation, which is a method of valuing Hoth Therapeutics by comparing valuation metrics of similar companies.Hoth Therapeutics is currently under evaluation in net income category among its peers.
Hoth Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Hoth Therapeutics from analyzing Hoth Therapeutics' financial statements. These drivers represent accounts that assess Hoth Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Hoth Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 14.7M | 9.3M | 4.9M | 4.8M | 5.5M | 5.2M | |
| Enterprise Value | 6.2M | 2.9M | (4.3M) | (2.2M) | (2.6M) | (2.4M) |
Hoth Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Hoth Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Hoth Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Hoth Therapeutics' value.| Shares | Federation Des Caisses Desjardins Du Quebec | 2025-06-30 | 350 | Royal Bank Of Canada | 2025-06-30 | 240 | Bank Of America Corp | 2025-06-30 | 123 | Citigroup Inc | 2025-06-30 | 19.0 | Sbi Securities Co Ltd | 2025-06-30 | 13.0 | Wells Fargo & Co | 2025-03-31 | 0.0 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 0.0 | Flp Wealth Management, Llc | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-06-30 | 0.0 | Geode Capital Management, Llc | 2025-06-30 | 122.6 K | Ubs Group Ag | 2025-06-30 | 42.2 K |
Hoth Fundamentals
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.84 | ||||
| Current Valuation | 6.9 M | ||||
| Shares Outstanding | 15.51 M | ||||
| Shares Owned By Insiders | 3.57 % | ||||
| Shares Owned By Institutions | 8.30 % | ||||
| Number Of Shares Shorted | 321.35 K | ||||
| Price To Earning | (7.16) X | ||||
| Price To Book | 1.79 X | ||||
| EBITDA | 27.13 K | ||||
| Net Income | (8.19 M) | ||||
| Cash And Equivalents | 11.62 M | ||||
| Cash Per Share | 9.02 X | ||||
| Total Debt | 31.07 K | ||||
| Debt To Equity | 2.01 % | ||||
| Current Ratio | 15.74 X | ||||
| Book Value Per Share | 0.54 X | ||||
| Cash Flow From Operations | (6.98 M) | ||||
| Short Ratio | 1.20 X | ||||
| Earnings Per Share | (1.02) X | ||||
| Target Price | 5.0 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 14.74 M | ||||
| Total Asset | 7.71 M | ||||
| Retained Earnings | (60.41 M) | ||||
| Working Capital | 6.81 M | ||||
| Current Asset | 448.84 K | ||||
| Current Liabilities | 312.22 K | ||||
| Net Asset | 7.71 M |
About Hoth Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hoth Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hoth Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hoth Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is there potential for Pharmaceuticals market expansion? Will Hoth introduce new products? Factors like these will boost the valuation of Hoth Therapeutics. Market participants price Hoth higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Hoth Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.